Indices related to apo CII and CIII serum concentrations and coronary heart disease: A case-control study

Preventive Medicine

Volumn 37, Issue 1, 2003, Pages 18-22

  Gerber, Yariv ^a   Goldbourt, Uri ^b   Segev, Shlomo ^a   Harats, Dror ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Apo CII; Apo CIII; Case control studies; Coronary heart disease; Triglyceride; VLDL

Indexed keywords

APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0038173382     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-7435(03)00051-3     Document Type: Article

References (30)

1. Krauss R.M. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 81:1998;13B-17B.
2. Alaupovic P. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol. 263:1996;32-60.
3. Hodis H.N. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation. 99:1999;2852-2854.
4. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level a meta-analysis of population-based prospective studies . J Cardiovasc Risk. 3:1996;213-219.
5. Austin M.A., Hokanson J.E., Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 81:1998;7B-12B.
6. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 86:2000;943-949.
7. Haim M., Benderly M., Brunner D., Behar S., Graff E., Reicher-Reiss H., et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) registry. Circulation. 100:1999;475-482.
8. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 105:2002;310-315.
9. Gerber Y., Goldbourt U., Cohen H., Harats D. Association between serum apolipoprotein CII and coronary heart disease. Prev Med. 35:2002;42-47.
10. Luc G., Fievet C., Arveiler D., Evans A.E., Bard J.M., Cambien F., et al. Apolipoprotein CIII and E in apoB and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction the ECTIM study . J Lipid Res. 37:1996;508-517.
11. Chivot L., Mainard F., Bigot E., Bard J.M., Auget J.L., Madec Y., et al. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoprotein CIII and E. Atherosclerosis. 82:1990;205-211.
12. Blankenhorn D.H., Alaupovic P., Wickham E., Chin H.P., Azen P. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation. 81:1990;470-476.
13. Hodis H.N., Mack W.J., Azen S.P., Alaupovic P., Pogoda J.M., LaBree L., et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 90:1994;42-49.
14. Sacks F.M., Alaupovic P., Moye L.A., Cole T.G., Sussex B., Stampfer M.J., et al. VLDL, apolipoprotein B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation. 102:2000;1886-1892.
15. Graziani M.S., Zanolla L., Righetti G., Marchetti C., Zanotto G., Lupo A. Distribution of CII and CIII peptides in lipoprotein classes methods and clinical significance . Clin Chem. 40:1994;240-244.
16. Alessandri C., Basili S., Maurelli M., Andreozzi P., Colletta A., Paradiso M., et al. Apolipoproteins CII and CIII in peripheral arterial disease. Angiology. 45:1994;131-136.
17. Hodis H.N., Mack W.J. Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J. 19:(Suppl A):1998;A40-44.
18. Hodis H.N., Mack W.J. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol. 6:1995;209-214.
19. Koren E., Corder C., Mueller G., Centurion H., Hallum G., Fesmire J., et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis. 122:1996;105-115.
20. Olivecrona G., Olivecrona T. Triglyceride lipases and atherosclerosis. Curr Opin Lipidol. 6:1995;291-305.
21. Zilversmit D.B. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ Res. 33:1973;633-638.
22. Jong M.C., Hofker M.H., Havekes L.M. Role of apoCs in lipoprotein metabolism. Functional differences between apoC1, apoC2, and apoC3. Arterioscler Thromb Vasc Biol. 19:1999;472-484.
23. Alaupovic P. Use of apolipoprotein parameters and endpoints in drug development and approval processes. Am J Cardiol. 81:1998;40F-47F.
24. Fredenrich A., Giroux L.M., Tremblay M., Krimbou L., Davignon J., Cohn J.S. Plasma lipoprotein distribution of apo CIII in normolipidemic and hypertriglyceridemic subjects comparison of the apo CIII to apo E ratio in different lipoprotein fractions . J Lipid Res. 38:1997;1421-1432.
25. Le N.A., Gibson J.C., Ginsberg H.N. Independent regulation of plasma apolipoprotein CII and CIII concentrations in very low density and high density lipoproteins implications for the regulation of the catabolism of these lipoproteins . J Lipid Res. 29:1988;669-677.
26. Ginsberg H.N., Le N.A., Goldberg I.J., Gibson J.C., Rubinstein A., Wang-Iverson P., et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and A-I. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 78:1986;1287-1295.
27. Tam S.P., Dory L., Rubinstein D. Fate of apolipoproteins C-II, C-III, and E during lipolysis of human very low density lipoproteins in vitro. J Lipid Res. 22:1981;641-651.
28. Wang C.S., McConathy W.J., Kloer H.U., Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein CIII. J Clin Invest. 75:1985;384-390.
29. Alaupovic P. David Rubinstein memorial lecture the biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins . Can J Biochem. 59:1981;565-579.
30. Sacks F.M., Alaupovic P., Moye L.A. Effect of pravastatin on apolipoprotein B and CIII in very-low-density lipoproteins and low-density-lipoproteins. Am J Cardiol. 90:2002;165-167.